|1.||Kacsoh, Balint: 2 articles (05/2011 - 03/2009)|
|2.||Thomas, James L: 2 articles (05/2011 - 03/2009)|
|3.||Bucholtz, Kevin M: 2 articles (05/2011 - 03/2009)|
|4.||Frye, C A: 2 articles (12/2001 - 10/2001)|
|5.||Vongher, J M: 2 articles (12/2001 - 10/2001)|
|6.||Mack, Vance L: 1 article (03/2009)|
|7.||Sun, Jingping: 1 article (03/2009)|
|8.||Tshamala, M: 1 article (10/2003)|
|9.||Ducatelle, R: 1 article (10/2003)|
|10.||Coryn, M: 1 article (10/2003)|
10/01/2003 - "At day 49 of metoestrus, there was a significant reduction in the size of the uterine wall, mainly due to endometrial atrophy, and there was also a significant increase in the mucus-filled uterine lumen in the bitches that had been treated with epostane compared to the control bitches. "
|2.||Body Weight (Weight, Body)
01/01/1989 - "These results suggest that the minimally effective dose of epostane for application during metoestrus is approximately 2.5 mg/kg and the effective dose range is about 2.5-5.0 mg/kg body weight. "
02/01/1987 - "On d 109 of pregnancy, each sow received one of the following treatments: no epostane (Group C); one oral dose of 5 mg (Group O5) or 10 mg (Group O10) of epostane/kg of body weight; or a sc injection of 1 mg (Group I1) or 5 mg (Group I5) of epostane/kg of body weight. "
09/01/1990 - "In Phase I of this study to enhance ovulation rate and hence litter size, gilts received 0 (sham control), 0.625, 1.25, 2.5 or 5.0 mg epostane/kg body weight on Days 10, 11 and 12 of the oestrous cycle (5 gilts/group). "
10/01/1987 - " 3 women abandoned the Epostane regimen because of nausea. "
10/01/1987 - "Subjective side effects, especially nausea, were more common in the women treated with Epostane, but no serious side effects were seen. "
09/29/1988 - "Nausea was frequent (in 86 percent), but 76 percent of the participants concluded that epostane was preferable to dilation and curettage. "
09/01/1988 - " Nausea occurred more often with 800 mg/day epostane than with 50 or 100 mg mifepristone. "
12/01/2001 - "Radioimmunoassay revealed that concentrations of midbrain 3alpha,5alpha-THP were reduced following epostane, finasteride or indomethacin infusions that significantly decreased lordosis. "
12/01/2001 - "Epostane, finasteride and indomethacin to the VTA significantly reduced lordosis, compared to vehicle infusions, in hormone-primed and behavioural oestrous rats and hamsters. "
10/01/2001 - "RU38486, a PR antagonist, attenuated lordosis of C57 and C57x129, but not PRKO, mice; epostane, a progestin biosynthesis inhibitor, reduced plasma progestins; and finasteride, a P metabolism inhibitor, reduced plasma 3alpha,5alpha-THP and attenuated lordosis of all mice. "
|5.||Breast Neoplasms (Breast Cancer)
05/01/2011 - "In our recombinant human breast tumor MCF-7 Tet-off cells that express either 3β-HSD1 or 3β-HSD2, trilostane and epostane inhibit the DHEA-induced proliferation of MCF-7 3β-HSD1 cells with 12-16-fold lower IC(50) values compared to the MCF-7 3β-HSD2 cells. "
03/25/2009 - "In our recombinant human breast tumor MCF-7 Tet-off cells that express either 3beta-HSD1 or 3beta-HSD2, trilostane and epostane inhibit the DHEA-induced proliferation of MCF-7 3beta-HSD1 cells with 12- to 16-fold lower IC(50) values compared to the MCF-7 3beta-HSD2 cells. "
|1.||salicylhydroxamic acid (SHAM)
|3.||Mifepristone (RU 486)